Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (21-30 of 189) with videos related to

Pageof 19
Sort By:
Science Translational Medicine|April 9, 2010
The road we must take: multidisciplinary team scienceMary L Disis, John T Slattery
Gynecologic Oncology|June 27, 2013
Therapeutic vaccines for ovarian cancerJohn B Liao, Mary L Disis
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Triple-negative breast cancer: immune modulation as the new treatment paradigmMary L Disis, Sasha E Stanton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Can immunity to breast cancer eliminate residual micrometastases?Mary L Disis, Sasha E Stanton
Breast Cancer Research and Treatment|August 2, 2002
Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patientsKathy Schiffman, Kristine Rinn, Mary L Disis
Expert Opinion on Therapeutic Targets|January 18, 2007
Targeting serum antibody for cancer diagnosis: a focus on colorectal cancerHailing Lu, Vivian Goodell, Mary L Disis
Journal of Proteome Research|March 4, 2008
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancerHailing Lu, Vivian Goodell, Mary L Disis
BMC Immunology|May 31, 2008
His-tag ELISA for the detection of humoral tumor-specific immunityVivian Goodell, Douglas McNeel, Mary L Disis
Lancet (London, England)|February 24, 2009
Use of tumour-responsive T cells as cancer treatmentMary L Disis, Helga Bernhard, Elizabeth M Jaffee
Chinese Clinical Oncology|May 10, 2017
Next generation approaches for tumor vaccinationAnand Patel, Howard L Kaufman, Mary L Disis
Pageof 19

Showing results (21-30 of 189) with videos related to

Sort By:
Pageof 19
Science Translational Medicine|April 9, 2010
The road we must take: multidisciplinary team scienceMary L Disis, John T Slattery
Gynecologic Oncology|June 27, 2013
Therapeutic vaccines for ovarian cancerJohn B Liao, Mary L Disis
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Triple-negative breast cancer: immune modulation as the new treatment paradigmMary L Disis, Sasha E Stanton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Can immunity to breast cancer eliminate residual micrometastases?Mary L Disis, Sasha E Stanton
Breast Cancer Research and Treatment|August 2, 2002
Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patientsKathy Schiffman, Kristine Rinn, Mary L Disis
Expert Opinion on Therapeutic Targets|January 18, 2007
Targeting serum antibody for cancer diagnosis: a focus on colorectal cancerHailing Lu, Vivian Goodell, Mary L Disis
Journal of Proteome Research|March 4, 2008
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancerHailing Lu, Vivian Goodell, Mary L Disis
BMC Immunology|May 31, 2008
His-tag ELISA for the detection of humoral tumor-specific immunityVivian Goodell, Douglas McNeel, Mary L Disis
Lancet (London, England)|February 24, 2009
Use of tumour-responsive T cells as cancer treatmentMary L Disis, Helga Bernhard, Elizabeth M Jaffee
Chinese Clinical Oncology|May 10, 2017
Next generation approaches for tumor vaccinationAnand Patel, Howard L Kaufman, Mary L Disis
Pageof 19